Atenolol-Sobhan

  • #
    medicine name: Atenolol-Sobhan
  • #
    Generic name: Atenolol
  • #
    Medication Shape: Oral tablets
  • #
    Packing: Box of 10 blisters of 10 scored F.C. tablets
  • #
    Pharmaceutical group: Cardiovascular

Indications:

Treatment of HTN alone or with other antihypertensives. 
Long-term management of angina pectoris. 
Management of hemodynamically stable patients with definite or suspected acute MI to reduce cardiovascular mortality.             

Method of Use:

Adult Dosage:
Hypertension: Initial: 50mg qd, either alone or w/ diuretic therapy.Titrate: May increase to 100mg qd after 1-2 weeks.Max:100mg qd
Angina Pectoris:Long-term Management: Initial:50mg qd.Titrate: May increase to 100mg qd after 1 week.Max: 200mg qd.
Acute Myocardial Infarction: Management of hemodynamically stable patients with definite/suspected acute MI to reduce cardiovascular mortality. Usual: Following IV dose, 50mg 10 min after IV dose followed by 50mg 12 hrs later, then 100mg qd or 50mg bid for 6-9 days or until discharge from the hospital. Atenolol is an additional treatment to standard coronary unit therapy.
Dosing Considerations:
Renal Impairment:
Max Dose for CrCl 15-35mL/min: 50mg/day 
Max Dose for CrCl <15mL/min: 25mg/day
Hemodialysis:  25mg or 50mg after each dialysis
HTN: Initial: May require a lower dose of 25mg qd
Elderly:

HTN:  Initial: May require a lower dose of 25mg qd

prohibited usage:

Known hypersensitivity to the active substance, or any of the excipients.
Cardiogenic shock
Uncontrolled heart failure
Sick sinus syndrome
Second-or third-degree heart block
Untreated pheochromocytoma
Metabolic acidosis
Bradycardia (< 50 bpm before treatment initiation)
Hypotension
Severe peripheral arterial circulatory disturbances
Severe asthma and severe chronic obstructive pulmonary disorders, such as airway obstructions
The intravenous application of calcium channel blockers (verapamil / diltiazem type) is contraindicated in patients who use atenolol (except in intensive care unit)